Community pharmacy provision of allergic rhinitis treatments

a longitudinal study of patient reported outcome

H. K. Sinclair, C. M. Bond, G. Largue, David Brendan Price, P. C. Hannaford

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective To monitor and compare the symptoms, and reported quality of life, of two groups of people who obtained treatment for allergic rhinitis from community pharmacies (prescribed or purchased).
Method Subjects were recruited by 64 community pharmacies in 2001 and followed up by postal questionnaire at four time points: five days, four weeks, eight weeks and 26 weeks. Setting Primary care: community pharmacies in Grampian, Scotland.
Results Response rates: five days — 84%; four weeks — 63%; eight weeks — 59%; 26 weeks — 56%. Three hundred and twenty-four subjects completed the five-day questionnaire (138 prescribed, 186 purchased). There were no important differences between groups in socio-economic variables monitored. The commonest treatments provided were antihistamines (non-sedating: 63% prescribed, 59% purchased; sedating: 3% prescribed, 16% purchased). Despite treatment, symptoms and quality-of-life impairments remained high; the prescribed group reported higher levels of many symptoms (including asthma), and lower quality of life at early time points. Most were satisfied with their treatment and few reported unmet need for pharmacy advice (11% prescribed, 3% purchased group).
Conclusion Despite high levels of patient satisfaction with allergic rhinitis treatment, symptoms and quality-of-life impairments remained high in both groups. Widespread implementation of ‘allergic rhinitis and its impact on asthma’ (ARIA) guidelines for physicians and for pharmacists might improve management of symptoms and quality of life of patients.
Original languageEnglish
Pages (from-to)249-256
Number of pages8
JournalInternational Journal of Pharmacy Practice
Volume13
Issue number4
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Pharmacies
Histamine Antagonists
Longitudinal Studies
Quality of Life
Economics
Asthma
Histamine H1 Antagonists
Therapeutics
Scotland
Patient Satisfaction
Pharmacists
Primary Health Care
Allergic Rhinitis
Patient Reported Outcome Measures
Guidelines
Physicians
Surveys and Questionnaires

Cite this

Community pharmacy provision of allergic rhinitis treatments : a longitudinal study of patient reported outcome. / Sinclair, H. K.; Bond, C. M.; Largue, G.; Price, David Brendan; Hannaford, P. C.

In: International Journal of Pharmacy Practice, Vol. 13, No. 4, 12.2005, p. 249-256.

Research output: Contribution to journalArticle

@article{10b20c6ccf964de6b6a7a44db6a9e4af,
title = "Community pharmacy provision of allergic rhinitis treatments: a longitudinal study of patient reported outcome",
abstract = "Objective To monitor and compare the symptoms, and reported quality of life, of two groups of people who obtained treatment for allergic rhinitis from community pharmacies (prescribed or purchased). Method Subjects were recruited by 64 community pharmacies in 2001 and followed up by postal questionnaire at four time points: five days, four weeks, eight weeks and 26 weeks. Setting Primary care: community pharmacies in Grampian, Scotland. Results Response rates: five days — 84{\%}; four weeks — 63{\%}; eight weeks — 59{\%}; 26 weeks — 56{\%}. Three hundred and twenty-four subjects completed the five-day questionnaire (138 prescribed, 186 purchased). There were no important differences between groups in socio-economic variables monitored. The commonest treatments provided were antihistamines (non-sedating: 63{\%} prescribed, 59{\%} purchased; sedating: 3{\%} prescribed, 16{\%} purchased). Despite treatment, symptoms and quality-of-life impairments remained high; the prescribed group reported higher levels of many symptoms (including asthma), and lower quality of life at early time points. Most were satisfied with their treatment and few reported unmet need for pharmacy advice (11{\%} prescribed, 3{\%} purchased group). Conclusion Despite high levels of patient satisfaction with allergic rhinitis treatment, symptoms and quality-of-life impairments remained high in both groups. Widespread implementation of ‘allergic rhinitis and its impact on asthma’ (ARIA) guidelines for physicians and for pharmacists might improve management of symptoms and quality of life of patients.",
author = "Sinclair, {H. K.} and Bond, {C. M.} and G. Largue and Price, {David Brendan} and Hannaford, {P. C.}",
year = "2005",
month = "12",
doi = "10.1211/ijpp.13.4.0003",
language = "English",
volume = "13",
pages = "249--256",
journal = "International Journal of Pharmacy Practice",
issn = "0961-7671",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "4",

}

TY - JOUR

T1 - Community pharmacy provision of allergic rhinitis treatments

T2 - a longitudinal study of patient reported outcome

AU - Sinclair, H. K.

AU - Bond, C. M.

AU - Largue, G.

AU - Price, David Brendan

AU - Hannaford, P. C.

PY - 2005/12

Y1 - 2005/12

N2 - Objective To monitor and compare the symptoms, and reported quality of life, of two groups of people who obtained treatment for allergic rhinitis from community pharmacies (prescribed or purchased). Method Subjects were recruited by 64 community pharmacies in 2001 and followed up by postal questionnaire at four time points: five days, four weeks, eight weeks and 26 weeks. Setting Primary care: community pharmacies in Grampian, Scotland. Results Response rates: five days — 84%; four weeks — 63%; eight weeks — 59%; 26 weeks — 56%. Three hundred and twenty-four subjects completed the five-day questionnaire (138 prescribed, 186 purchased). There were no important differences between groups in socio-economic variables monitored. The commonest treatments provided were antihistamines (non-sedating: 63% prescribed, 59% purchased; sedating: 3% prescribed, 16% purchased). Despite treatment, symptoms and quality-of-life impairments remained high; the prescribed group reported higher levels of many symptoms (including asthma), and lower quality of life at early time points. Most were satisfied with their treatment and few reported unmet need for pharmacy advice (11% prescribed, 3% purchased group). Conclusion Despite high levels of patient satisfaction with allergic rhinitis treatment, symptoms and quality-of-life impairments remained high in both groups. Widespread implementation of ‘allergic rhinitis and its impact on asthma’ (ARIA) guidelines for physicians and for pharmacists might improve management of symptoms and quality of life of patients.

AB - Objective To monitor and compare the symptoms, and reported quality of life, of two groups of people who obtained treatment for allergic rhinitis from community pharmacies (prescribed or purchased). Method Subjects were recruited by 64 community pharmacies in 2001 and followed up by postal questionnaire at four time points: five days, four weeks, eight weeks and 26 weeks. Setting Primary care: community pharmacies in Grampian, Scotland. Results Response rates: five days — 84%; four weeks — 63%; eight weeks — 59%; 26 weeks — 56%. Three hundred and twenty-four subjects completed the five-day questionnaire (138 prescribed, 186 purchased). There were no important differences between groups in socio-economic variables monitored. The commonest treatments provided were antihistamines (non-sedating: 63% prescribed, 59% purchased; sedating: 3% prescribed, 16% purchased). Despite treatment, symptoms and quality-of-life impairments remained high; the prescribed group reported higher levels of many symptoms (including asthma), and lower quality of life at early time points. Most were satisfied with their treatment and few reported unmet need for pharmacy advice (11% prescribed, 3% purchased group). Conclusion Despite high levels of patient satisfaction with allergic rhinitis treatment, symptoms and quality-of-life impairments remained high in both groups. Widespread implementation of ‘allergic rhinitis and its impact on asthma’ (ARIA) guidelines for physicians and for pharmacists might improve management of symptoms and quality of life of patients.

U2 - 10.1211/ijpp.13.4.0003

DO - 10.1211/ijpp.13.4.0003

M3 - Article

VL - 13

SP - 249

EP - 256

JO - International Journal of Pharmacy Practice

JF - International Journal of Pharmacy Practice

SN - 0961-7671

IS - 4

ER -